Ocular Blood Flow Imaging for Glaucoma Assessment

Glaucoma Clinical Trial

Official title:

Ocular Blood Flow Imaging for Glaucoma Assessment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05726058
• Other study ID #: HP-00102645
• Secondary ID: 1R44EY034064-01
• Status: Recruiting
• Phase: N/A
• Start date: March 30, 2023
• Est. completion date: April 30, 2025

Study information

• Verified date: April 2024
• Source: University of Maryland, Baltimore
• Contact: Osamah J Saeedi, MD, MS
• Phone: (410) 328-5929
• Email: osaeedi[@]som.umaryland.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to investigate the use of an FDA-cleared retinal blood flow imaging instrument called the XyCAM RI and XyCAM FC (Vasoptic Medical, Inc., Columbia, MD) in glaucoma management.

The main question it aims to answer are:

• Can the investigators use blood flow to discriminate between eyes with early-stage glaucoma and variable-matched controls?

• Can the investigators validate that the XyCAM FC simultaneously captures both stereo fundus photography and ocular blood flow monitoring?

Participants will be

• measured for their blood pressure, heart rate, height, and weight

• dilated with tropicamide

• imaged using the XyCAM RI, fundus photography, optical coherence tomography, and standard automated perimetry

• imaged using the XyCAM RI while inhaling 100% oxygen through a mask

Description:

The investigators will capture images of the participant's retina using the XyCAM RI or XyCAM FC ("test data") and by color fundus photography, optical coherence tomography (OCT), and standard automated perimetry (SAP) - the "standard clinical data". The investigators will perform five tests. The first two tests will be conducted using the XyCAM RI or XyCAM FC to obtain "test data". The final two tests will be conducted using routine clinical instruments to obtain "standard clinical data". The investigators will administer eye drops (Tropicamide) to dilate the participant's pupils prior to the first test. Tropicamide is a chemical that causes pupil dilation and is commonly used by doctors to examine the participant's eyes. The entire set of test data sessions should last less than eighty (80) minutes with an additional 60 minutes for carrying out the necessary procedures and imaging using the standard clinical data.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: April 30, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 88 Years

Eligibility

Inclusion Criteria:

• Age 18 and older with binocular vision

• Able to provide informed consent

• Patient is a healthy control OR is recommended for glaucoma assessment OR diagnosed with moderate to severe glaucoma in at least one eye as determined by Hodapp Anderson Criteria

Exclusion Criteria:

• The subject has significant media opacity (e.g., a visually significant cataract or significant corneal scar)

• The subject has previous ocular surgery other than uncomplicated cataract extraction, laser trabeculoplasty (ALT or SLT), or YAG capsulotomy

• The subject has prior ocular disease other than glaucoma

• The subject has anatomically narrow angles or a prior adverse reaction to administration of Tropicamide or fluorescein dye

• The subject has more than 15 diopters of refractive error

• The subject is a female who is pregnant or nursing

• The subject has diabetes mellitus

Related Conditions & MeSH terms

• Glaucoma

Intervention

Device:
• XyCAM with oxygen
After the standard imaging protocols, participants will be asked to inhale 100% oxygen through a mask and will be re-imaged using the XyCAM RI or XyCAM FC.

Locations

Country	Name	City	State
United States	University of Maryland Eye Associates at Redwood	Baltimore	Maryland

Sponsors (3)

Lead Sponsor	Collaborator
University of Maryland, Baltimore	National Eye Institute (NEI), Vasoptic Medical, Inc

Country where clinical trial is conducted

United States, 

References & Publications (1)

Vinnett A, Kandukuri J, Le C, Cho KA, Sinha A, Asanad S, Thompson G, Chen V, Rege A, Saeedi OJ. Dynamic Alterations in Blood Flow in Glaucoma Measured with Laser Speckle Contrast Imaging. Ophthalmol Glaucoma. 2022 May-Jun;5(3):250-261. doi: 10.1016/j.ogla.2021.10.005. Epub 2021 Oct 18. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood flow velocity measure	Dynamic video of ocular blood flow	through study completion, an average of 1 year